북미, 유럽 및 아시아태평양의 고분자 바이오 분석 테스트 서비스 시장 예측(-2030년)

Market Overview

The market for large molecule bioanalysis testing services in North America, Europe, and Asia-Pacific is expanding due to rising demand for high-tech and dependable large molecule bioanalytical testing services, a growing trend of outsourcing laboratory testing services, and an increase in the number of clinical trials. However, the difficulties in developing appropriate analytical techniques are limiting the growth of the North America, Europe, and Asia-Pacific large molecule bioanalysis testing services market. Furthermore, the growing prevalence of chronic diseases is expected to provide lucrative growth opportunities for the North America, Europe, and Asia-Pacific large molecule bioanalysis testing services market.

The concentration of large molecules in biological samples such as proteins and antibodies are determined using large molecule bioanalytical testing services. Large molecules are frequently utilized in drug development, and bioanalytical testing is required to ensure these drugs' safety and efficacy.

The expected growth in market can be attributed to the increasing demand for high-tech and reliable large molecule bioanalytical testing services, growing trend of outsourcing laboratory testing services, and rising R&D expenditure in the biopharmaceutical sector. However, the market is also held back by challenges in the development of proper analytical techniques. Nevertheless, it is anticipated that the growing incidence of chronic diseases will create lucrative opportunities for the players operating in the North America, Europe, And Asia-Pacific large molecule bioanalysis testing services market.

MARKET SEGMENTATION

Based on test type, the large molecule bioanalysis testing market has been segmented into pharmacokinetic (PK) studies, pharmacodynamic studies, bioequivalence studies, immunogenicity testing, biomarker testing and others.

Based on therapeutic area, the market has been segmented into oncology, infectious diseases, cardiovascular diseases, neurology, autoimmune disorders, and others.

Based on test type, the market has been segmented into pharmaceutical and biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), academic and research institutes, and others.

Regional Analysis

Based on region, the large molecule bioanalysis testing services market has been segmented into North America, Europe, and Asia-Pacific. North America accounted for the largest market share of 45.29% in 2022 and is anticipated to reach approximately USD 1,498.85 million by 2030 at an 8.70% CAGR during the forecast period. However, Asia-Pacific is projected to register the highest CAGR of 11.52% by 2030.

MAJOR PLAYERS

America Holdings (US), ICON plc (Ireland), SGS Societe Generale de Surveillance SA (Switzerland), WuXi AppTec (China), Charles River Laboratories (US), Eurofins Scientific (luxembourg), QPS Holdings (US), BioTechne (US), PPD, Inc (US), BioAgilytix Labs (US), Smithers (US), Meso Scale Diagnostic, LLC (US), and CMIC HOLDINGS CO., LTD (Japan).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE
• 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING DEMAND FOR HIGH-TECH AND RELIABLE LARGE MOLECULE BIOANALYTICAL TESTING SERVICES
  • 4.2.2 GROWING TREND OF OUTSOURCING LABORATORY TESTING SERVICES
  • 4.2.3 RISING R&D EXPENDITURE IN THE BIOPHARMACEUTICAL SECTOR
• 4.3 RESTRAINTS
  • 4.3.1 CHALLENGES IN THE DEVELOPMENT OF PROPER ANALYTICAL TECHNIQUES
• 4.4 OPPORTUNITIES
  • 4.4.1 GROWING INCIDENCE OF CHRONIC DISEASES

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 CUSTOMER ACQUISITION (PRE-PURCHASE QUERY)
  • 5.1.2 SERVICE CUSTOMIZATION
  • 5.1.3 CUSTOMER PURCHASE SUPPORT
  • 5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET
  • 5.3.1 IMPACT ON SUPPLY CHAIN
  • 5.3.2 IMPACT ON SERVICE PROVIDER

6 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY TEST TYPE

• 6.1 OVERVIEW
• 6.2 PHARMACOKINETIC (PK) STUDIES
• 6.3 PHARMACODYNAMIC (PD) STUDIES
• 6.4 BIOEQUIVALENCE STUDIES
• 6.5 BIOMARKER TESTING
• 6.6 IMMUNOGENICITY TESTING
• 6.7 OTHERS

7 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY THERAPEUTIC AREA

• 7.1 OVERVIEW
• 7.2 ONCOLOGY
• 7.3 INFECTIOUS DISEASES
• 7.4 CARDIOVASCULAR DISEASE
• 7.5 NEUROLOGY
• 7.6 AUTOIMMUNE DISORDERS
• 7.7 OTHERS

8 NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
• 8.3 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS (CDMOS)
• 8.4 CONTRACT RESEARCH ORGANIZATIONS (CROS)
• 8.5 ACADEMIC AND RESEARCH INSTITUTES
• 8.6 OTHERS

9 NORTH AMERICA, EUROPE, ASIA-PACIFIC LARGE MOLECULE BIOANALYTICAL TESTING SERVICES MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 SWITZERLAND
  • 9.3.7 NETHERLANDS
  • 9.3.8 BELGIUM
  • 9.3.9 SWEDEN
  • 9.3.10 NORWAY
  • 9.3.11 DENMARK
  • 9.3.12 IRELAND
  • 9.3.13 FINLAND
  • 9.3.14 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 SOUTH KOREA
  • 9.4.5 AUSTRALIA
  • 9.4.6 REST OF ASIA-PACIFIC

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE BENCHMARKING
• 10.3 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY CATEGORY
  • 10.3.1 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY PHARMA
  • 10.3.2 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY CDMO
  • 10.3.3 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY CRO
  • 10.3.4 TOP COMPANIES FOR LARGE MOLECULE BIOANALYSIS, BY ACADEMIC AND RESEARCH INSTITUTIONS
• 10.4 MAJOR GROWTH STRATEGY IN THE NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET
• 10.5 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE NORTH AMERICA, EUROPE, AND ASIA-PACIFIC LARGE MOLECULE BIOANALYSIS TESTING SERVICES MARKET
• 10.6 KEY DEVELOPMENT ANALYSIS
• 10.7 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.7.1 EXPANSION
• 10.8 MAJOR PLAYERS FINANCIAL
  • 10.8.1 SALES (USD MILLION), 2022
  • 10.8.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2022

11 COMPANY PROFILES

• 11.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 SERVICES OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 PPD INC
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 SERVICES OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 EUROFINS SCIENTIFIC
  • 11.3.1 COMPANY OVERVIEWS
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 SERVICES OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 WUXI APPTEC
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 SERVICES OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 KEY STRATEGIES
• 11.5 QPS HOLDINGS
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 SERVICES OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 KEY STRATEGIES
• 11.6 BIO-TECHNE
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 SERVICES OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 KEY STRATEGIES
• 11.7 ICON PLC
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 SERVICES OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGIES
• 11.8 CHARLES RIVER LABORATORIES
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 SERVICES OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 SWOT ANALYSIS
  • 11.8.6 KEY STRATEGIES
• 11.9 SGS SOCIETE GENERALE DE SURVEILLANCE SA
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS/SERVICES OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 BIOAGILYTIX LABS
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 SERVICES OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 KEY STRATEGIES
• 11.11 SMITHERS
  • 11.11.1 COMPANY OVERVIEW
  • 11.11.2 FINANCIAL ANALYSIS
  • 11.11.3 SERVICES OFFERED
  • 11.11.4 KEY DEVELOPMENTS
  • 11.11.5 KEY STRATEGIES
• 11.12 MESO SCALE DIAGNOSTICS, LLC
  • 11.12.1 COMPANY OVERVIEW
  • 11.12.2 FINANCIAL ANALYSIS
  • 11.12.3 SERVICES OFFERED
  • 11.12.4 KEY DEVELOPMENTS
  • 11.12.5 KEY STRATEGIES
• 11.13 CMIC HOLDINGS CO., LTD
  • 11.13.1 COMPANY OVERVIEW
  • 11.13.2 FINANCIAL OVERVIEW
  • 11.13.3 SERVICES OFFERED
  • 11.13.4 KEY DEVELOPMENTS
  • 11.13.5 KEY STRATEGIES

12 REFERENCES

• 12.1 RELATED REPORTS